Plitidepsin

CHEMBL451930 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1110.3 g/mol

LogP

5.7

Phase

4

Plitidepsin is a cyclic depsipeptide of marine origin derived from the tunicate Aplidium albicans that exerts anticancer activity by inhibiting protein synthesis through binding to eukaryotic elongation factor 1A2 (eEF1A2), disrupting the elongation phase of translation. It has demonstrated activity in multiple myeloma, T-cell lymphoma, and leukemia, and has also shown antiviral activity against SARS-CoV-2.

Molecular Weight

1110.3000 g/mol

LogP

5.70

TPSA

285.00 Å²

Lipinski RO5

Fail

Therapeutic Areas

Leukemia Lymphoma Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O

InChI

InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1

Molecular Formula

C57H87N7O15

HBD / HBA

4 / 15

Rotatable Bonds

15

Heavy Atoms

79

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Plitidepsin is a cyclic depsipeptide of marine origin derived from the tunicate Aplidium albicans that exerts anticancer activity by inhibiting protein synthesis through binding to eukaryotic elongation factor 1A2 (eEF1A2), disrupting the elongation phase of translation. It has demonstrated activity in multiple myeloma, T-cell lymphoma, and leukemia, and has also shown antiviral activity against SARS-CoV-2.

Yes, Plitidepsin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL451930. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9812534. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Plitidepsin on PillFYI

Structure

Quick Data

Formula: C57H87N7O15

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.